Swallowing development in infants and toddlers with spinal muscular atrophy following therapy compared to healthy controls: the prospective controlled DySMA trial

BACKGROUND: Swallowing development is a crucial outcome measure for evaluating the effectiveness of disease-modifying therapies (DMT) in children with spinal muscular atrophy (SMA). However, data on this aspect remain limited due to a lack of assessment tools. This study aimed to evaluate swallowing development in infants and toddlers with SMA, compare it with healthy controls (HC), and investigate the influence of initial symptom status at start of DMT and SMN2 copy number. METHODS: An observational study was conducted with infants and toddlers diagnosed with SMA at a single neuropediatric center and a HC group. Swallowing development was primarily assessed using the DySMA scale. Group differences and the impact of initial symptom status and SMN2 copy number on swallowing were analyzed using linear mixed-effects models. RESULTS: The study included 127 infants and toddlers, 35 with SMA (0–36 months, 19 girls), who started DMT either presymptomatically (n = 18) or symptomatically (n = 17), with two (n = 26) or three (n = 9) SMN2 copies, predominantly receiving Onasemnogene abeparvovec alone (n = 26), and a healthy control group (n = 92, 0–23 months, 34 girls). Children with SMA displayed significantly different swallowing development trajectories (-0.06 DySMA points by months of life, p=.06; 95% CI -0.13 to 0.01) compared to HC (+ 0.45 DySMA points by months of life, p